Cystic Fibrosis Patients on Cystic Fibrosis Transmembrane Conductance Regulator Modulators Have a Reduced Incidence of Cirrhosis

Overview

Journal World J Hepatol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2022 Mar 23

PMID 35317183

Authors

Mitchell L Ramsey

Michael R Wellner

Kyle Porter

Stephen E Kirkby

Susan S Li

Luis F Lara

Sean G Kelly

A James Hanje

Lindsay A Sobotka

Affiliations

Soon will be listed here.

Abstract

Background: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators significantly improve pulmonary function in patients with cystic fibrosis (CF) but the effect on hepatobiliary outcomes remains unknown. We hypothesized that CF patients on CFTR modulators would have a decreased incidence of cirrhosis compared to patients not on CFTR modulators or on ursodiol.

Aim: To investigate the effect of CFTR modulators on the development of cirrhosis in patients with CF.

Methods: A retrospective analysis was performed using Truven MarketScan from January 2012 through December 2017 including all patients with a diagnosis of CF. Patients were excluded if they underwent a liver transplantation or if they had other etiologies of liver disease including viral hepatitis or alcohol use. Subjects were grouped by use of CFTR modulators, ursodiol, dual therapy, or no therapy. The primary outcome was development of cirrhosis. Kaplan-Meier curves estimated the incidence of cirrhosis and log-rank tests compared incidence curves between treatment groups.

Results: A total of 7201 patients were included, of which 955 (12.6%) used a CFTR modulator, 529 (7.0%) used ursodiol, 105 (1.4%) used combination therapy, and 5612 (74.3%) used neither therapy. The incidence of cirrhosis was 0.1% at 1 year and 0.7% at 4 years in untreated patients, 5.9% and 10.1% in the Ursodiol group, and 1.0% and 1.0% in patients who received both therapies. No patient treated with CFTR modulators alone developed cirrhosis. Patients on CFTR modulators alone had lower cirrhosis incidence than untreated patients ( = 0.05), patients on Ursodiol ( < 0.001), and patients on dual therapy ( = 0.003). The highest incidence of cirrhosis was found among patients treated with Ursodiol alone, compared to untreated patients ( < 0.001) or patients on Ursodiol and CFTR modulators ( = 0.01).

Conclusion: CFTR modulators are associated with a reduction in the incidence of cirrhosis compared to other therapies in patients with CF.

Citing Articles

Impact of CFTR modulatory therapies on liver function and fibrosis indices in cystic fibrosis patients: a retrospective analysis from two Romanian medical centers.

Moiceanu E, Stan I, Mosescu S, Leucuta D, Iacobescu M, Nitescu G Med Pharm Rep. 2025; 98(1):29-35.

PMID: 39949910 PMC: 11817584. DOI: 10.15386/mpr-2806.

Macroenzymes as a reason for aminotransferases flare in cystic fibrosis patients on CFTR modulators therapy - Report of three cases.

Woynarowski M, Sapiejka E, Jozwiak M, Milczewska J, Zybert K, Krusinski A Heliyon. 2024; 10(10):e31189.

PMID: 38813168 PMC: 11133693. DOI: 10.1016/j.heliyon.2024.e31189.

Increased aminotransferases do not necessarily mean hepatotoxicity of CFTR modulator therapy.

Woynarowski M, Sapiejka E, Jozwiak M, Wierzbicka-Rucinska A Clin Exp Hepatol. 2024; 9(4):405-409.

PMID: 38774202 PMC: 11103804. DOI: 10.5114/ceh.2023.132264.

The Role of Cystic Fibrosis Transmembrane Conductance Regulator Modulators After Liver Transplantation in Persons With Cystic Fibrosis.

Maradiaga R, Ramsey M, Kirkby S, Sobotka L ACG Case Rep J. 2024; 11(1):e01261.

PMID: 38234978 PMC: 10793987. DOI: 10.14309/crj.0000000000001261.

Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations.

Sellers Z, Assis D, Paranjape S, Sathe M, Bodewes F, Bowen M Hepatology. 2023; 79(5):1220-1238.

PMID: 37934656 PMC: 11020118. DOI: 10.1097/HEP.0000000000000646.

References

Feranchak A . Hepatobiliary complications of cystic fibrosis. Curr Gastroenterol Rep. 2004; 6(3):231-9. DOI: 10.1007/s11894-004-0013-6. View

Keating D, Marigowda G, Burr L, Daines C, Mall M, McKone E . VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018; 379(17):1612-1620. PMC: 6289290. DOI: 10.1056/NEJMoa1807120. View

Victor K, Randen I, Thompson K, Forre O, Natvig J, Fu S . Rheumatoid factors isolated from patients with autoimmune disorders are derived from germline genes distinct from those encoding the Wa, Po, and Bla cross-reactive idiotypes. J Clin Invest. 1991; 87(5):1603-13. PMC: 295243. DOI: 10.1172/JCI115174. View

Merli M, Bertasi S, Servi R, Diamanti S, Martino F, DE Santis A . Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: a randomized, placebo-controlled, crossover trial. J Pediatr Gastroenterol Nutr. 1994; 19(2):198-203. DOI: 10.1097/00005176-199408000-00010. View

Flume P, OSullivan B, Robinson K, Goss C, Mogayzel Jr P, Willey-Courand D . Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007; 176(10):957-69. DOI: 10.1164/rccm.200705-664OC. View

VAWTER G, SHWACHMAN H . Cystic fibrosis in adults: an autopsy study. Pathol Annu. 1979; 14 Pt 2:357-82. View

Lopes-Pacheco M . CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Front Pharmacol. 2020; 10:1662. PMC: 7046560. DOI: 10.3389/fphar.2019.01662. View

Sobotka L, Hinton A, Conteh L . African Americans are less likely to receive curative treatment for hepatocellular carcinoma. World J Hepatol. 2018; 10(11):849-855. PMC: 6280157. DOI: 10.4254/wjh.v10.i11.849. View

Leung D, Narkewicz M . Cystic Fibrosis-related cirrhosis. J Cyst Fibros. 2017; 16 Suppl 2:S50-S61. DOI: 10.1016/j.jcf.2017.07.002. View

10.

Leeuwen L, Fitzgerald D, Gaskin K . Liver disease in cystic fibrosis. Paediatr Respir Rev. 2013; 15(1):69-74. DOI: 10.1016/j.prrv.2013.05.001. View

11.

Condren M, Bradshaw M . Ivacaftor: a novel gene-based therapeutic approach for cystic fibrosis. J Pediatr Pharmacol Ther. 2013; 18(1):8-13. PMC: 3626070. DOI: 10.5863/1551-6776-18.1.8. View

12.

Middleton P, Mall M, Drevinek P, Lands L, McKone E, Polineni D . Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019; 381(19):1809-1819. PMC: 7282384. DOI: 10.1056/NEJMoa1908639. View

13.

Genta R, Sonnenberg A . Big data in gastroenterology research. Nat Rev Gastroenterol Hepatol. 2014; 11(6):386-90. DOI: 10.1038/nrgastro.2014.18. View

14.

Flume P, Mogayzel Jr P, Robinson K, Rosenblatt R, Quittell L, Marshall B . Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med. 2010; 182(3):298-306. DOI: 10.1164/rccm.201002-0157OC. View

15.

Kutney K, Donnola S, Flask C, Gubitosi-Klug R, ORiordan M, McBennett K . Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. World J Hepatol. 2020; 11(12):761-772. PMC: 6960296. DOI: 10.4254/wjh.v11.i12.761. View

16.

OBrien S, Campbell G, Burke A, Maguire O, Rowlands B, Fitzgerald M . Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease. Eur J Gastroenterol Hepatol. 1996; 8(5):477-83. View

17.

Sobotka L, Spitzer C, Hinton A, Michaels A, Hanje A, Mumtaz K . Management of hepatic hydrothorax and effect on length of stay, mortality, cost, and 30-day hospital readmission. J Gastroenterol Hepatol. 2019; 35(4):641-647. DOI: 10.1111/jgh.14842. View

18.

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

19.

Bessonova L, Volkova N, Higgins M, Bengtsson L, Tian S, Simard C . Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax. 2018; 73(8):731-740. PMC: 6204955. DOI: 10.1136/thoraxjnl-2017-210394. View

20.

Habib A, Kajbafzadeh M, Desai S, Yang C, Skolnik K, Quon B . A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis. Sci Rep. 2019; 9(1):7234. PMC: 6510767. DOI: 10.1038/s41598-019-43652-2. View